Lower House approves bills to raise out-of-pocket costs for OTC-like drugs

The approval of this legislation reflects a significant shift in Japan's healthcare policy, emphasizing cost-sharing in the pharmaceutical sector. While the intention may be to alleviate financial burdens on the healthcare system, the increased costs for patients could lead to reduced access to necessary medications, particularly for those with chronic conditions. The exceptions for cancer and intractable diseases suggest a recognition of the need for continued support in these critical areas, but overall, this policy may disproportionately affect lower-income individuals.